Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor

Annals of Internal Medicine

Volumn 118, Issue 4, 1993, Pages 246-254

  Keilani, Taha ^a   Schlueter, William A ^a   Levin, Murray L ^a   Batlle, Daniel C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FAT INTAKE; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN METABOLISM; PROTEINURIA;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FOSINOPRIL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY DISEASES; LIPOPROTEIN(A); MALE; MIDDLE AGE; PROTEINURIA; SUPPORT, NON-U.S. GOV'T;

EID: 0027474530     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-118-4-199302150-00002     Document Type: Article

References (38)

1. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987;10:157-71.
2. Mutin MJ, Hulley SB, Browner WS, Kuller LA, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet. 1986;934-6.
3. Curry RC Jr, Roberts WC. Status of the coronary arteries in the nephrotic syndrome. Am J Med. 1977;63:183-92.
4. Kandi L Romics L, Palos G, Doman J, Kaszas I, Hesz A, et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem. 1989;35:2121-3.
5. Scann AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-15.
6. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-92.
7. Kasiske BL, O'Donnedl MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zuker rats. Kidney Int. 1988;33:667-72.
8. Keane WF, Kasiske BL. Hyperlipidemia in the nephrotic syndrome [Editorial]. N Engl J Med. 1990;323:603-4.
9. Moorehead JF, Chan MK, El Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubule-interstitial disease. Lancet. 1982;1309-11.
10. Diamond JR, Karnovsky MJ. Focal and segmentai glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988;33:917-24.
11. Anderson S, Rennke HG, Bremer BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
12. Meyer TW, Anderson S, Renke HG, Breaner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987;31:752-9.
13. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzl G. Angiotensin converting enzyme inhibition ameliorates glomenilar filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin invest. 1990;85:541-9.
14. Marre M, Leblanc H, Suarez L, Guyenne TT, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J. 1987; 294:1448-52.
15. Bjork S, Nybert G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J. 1986;293:471-4.
16. Tagnma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313:1617-20.
17. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272-9.
18. Ruilope LM, Miranda B, Oliet A, Millet VG, Rodicio JL, Romero JC, et al. Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria. J Hypertens. 1988;6(Suppl. 4):S467-9.
19. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988;25:9-15.
20. Glassock RJ. Syndromes of glomerular diseases. Textbook of Nephrology. v 1. Massry SG, Glassock RJ; eds. Baltimore: Williams & Wilkins. 1983:6.3-6.64.
21. Burnstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteines from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-95.
22. Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay for Lp(a). J Lipid Res. 1989;30:651-62.
23. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin converting enzyme of rabbit lung. Biochem Pharmocol. 1971;20:1637.
24. Leren TP, Hjermann L, Berg K, Leren P, Fou OP, Vlksmoen L. Effect of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 1988;73:135-41.
25. Kostner GM, Garish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-9.
26. Davies RW, Staprans I, Hotchison FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest. 1990;86:600-5.
27. Javen J, Villabona C, Vilella E, Masana L, Albert R, Valles M. Abnormalities of lipopotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323:579-84.
28. Kasiske BL,Vellosa JA, Halstenson CE, La Belle P, Lugendorfer A, Keane WF. The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis. 1990;15:8-15.
29. Golper TA, Illingworth DR, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis. 1989;13:312-20.
30. Schlueter WA, Batlle DC. Renal effects of antihypertensive drugs. Drugs. 1989;37:900-25.
31. Appel GB, Blum CB, Chien S, Knnis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med. 1985; 312:1544-8.
32. Allen JC, Baxter JH, Goodman JC. Effects of dextran, poryvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis. J Clin Invest. 1961;40:499-508.
33. Staprans I, Felts JM, Couser WG. Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism. 1987; 36:496-501.
34. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin synthesis, albuminuria and hyperlipidemia in nephrotic patients. Kidney Int. 1987;31:1368-76.
35. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restriction dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78-84.
36. Bakris GL. Effect of diltiazem or Iisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-8.
37. Demarie BK, Bakris GL. Effect of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;113:987-8.
38. Hosfetter TH. Pathogenesis of diabetic glomerulopathy: bemodynamic considerations. Semin Nephrol. 1990;10(3):219-27.